William D. McCombe is CFO at Cytek Biosciences, Inc. (CTKB). They have made 5 open-market trades across 2 companies since 2022, most recently 2026-08-18.
CIK 0001878824
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $97K since 2025, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTKB | BUY | 2025-06-02 | 2025-06-03 | $2.78 | $97K | +8.8% | +27.0% | +35.8% |
| VLD | SELL | 2023-08-21 | 2023-08-23 | $1.49 | $17K | -7.8% | -15.1% | -39.2% |
| VLD | SELL | 2023-05-15 | 2023-05-16 | $1.86 | $21K | -4.5% | +6.3% | -15.3% |
| VLD | SELL | 2023-02-15 | 2023-02-17 | $3.62 | $15K | -16.3% | -34.9% | -48.2% |
| VLD | SELL | 2022-11-16 | 2022-12-14 | $2.61 | $38K | -5.8% | +23.4% | +53.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.